Trial · NCT05381363
Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
NCT05381363, Phase 1, Phase 2, Terminated, Children's Hospital of Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children. Trials, record NCT05381363. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05381363
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
- NCT number
- NCT05381363
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 24 participants, actual
- Lead sponsor
- Children's Hospital of Fudan University
- Conditions
- COVID-19, Children
- Interventions
- Inhaled Interferon α2b, Standard of Care
- First posted
- 2022-05-19
- Last updated
- 2023-12-29
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Days requiring isolation (DRI) | from symptom onset to point of de-isolation (about 2-3 weeks) | Efficacy of inhaled Interferon α2b by assessment of the Days requiring isolation (DRI). Patients will receive daily PCR. Nasal swab specimens were collected by standard procedures performed by trained nurses. |
| Secondary | Duration of fever | from fever onset to free from fever (about 2-3 weeks) | Efficacy of inhaled Interferon α2b by assessment of the duration of fever. |
| Secondary | Proportions of COVID-19 symptoms | from symptom onset to point of de-isolation (about 2-3 weeks) | Efficacy of inhaled Interferon α2b by assessment of the duration of COVID-10 symptoms including fever, cough, sore throat, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell. |
| Secondary | Blood test | Every 3 days (from the date of hospitalization to point of de-isolation) | This test including the count of leukocytes, neutrophils, lymphocytes, platelets, and hemoglobin in plasma. Inflammatory Biomarker. |
| Secondary | C-reactive protein (CRP) | Every 3 days (from the date of hospitalization to point of de-isolation) | Inflammatory Biomarker |
| Secondary | Interleukin 6 (IL-6) | Every 3 days (from the date of hospitalization to point of de-isolation) | Inflammatory Biomarker |
| Secondary | Chest imaging findings | once on admission | Imaging evaluation methods |
| Secondary | Number of Adverse Events (Abnormal Appearance) | From Day 1 to time point of de-isolation post-dose in each period (about 2-3 weeks) | This is a composition of obviously severe flu-like symptoms, including nausea, fatigue, weight loss. |
| Secondary | Number of Adverse Events (Abnormal Hematology) | From Day 1 to time point of de-isolation post-dose in each period (about 2-3 weeks) | Safety of inhaled Interferon α2b by assessment of safety laboratory tests. |
| Secondary | Number of Adverse Events (Abnormal Clinical Chemistry) | From Day 1 to time point of de-isolation post-dose in each period (about 2-3 weeks) | Safety of inhaled Interferon α2b by assessment of safety laboratory tests. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05381363
GET https://conductscience.org/api/trials/v1/NCT05381363/registered